Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002044 · ClinicalTrials.gov registry record · NA
A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases
A NA study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- NA
- Development phase
NCT00002044: Completed NA study, sponsored by Glaxo Wellcome.
NCT00002044 is a NA study that has completed, run by Glaxo Wellcome. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002044, a NA study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- NA
- Development phase
Study Summary
The purpose of this pilot study is to evaluate the efficacy of Retrovir (AZT) in the treatment of AIDS-related dementia and various neuromuscular complications. HIV is both a lymphotropic and neurotropic virus which can affect both the central and peripheral nervous systems (CNS, PNS). There is evidence that the CNS and PNS may harbor the virus in a latent state, with the potential for continuous reinfection of other body systems. Therefore, effective therapeutic efforts against HIV infection should provide effective antiviral activity within the nervous system.
Interventions
- DRUG Zidovudine
Trial Details
| Field | Value |
|---|---|
| Phase | NA |
What the finished NCT00002044 record still lists
NCT00002044 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Zidovudine is the first listed.
NCT00002044 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002044 about?
NCT00002044 is a clinical study titled "A Pilot Study To Evaluate the Effect of Retrovir (Zidovudine: AZT) in the Treatment of Human Immunodeficiency Virus (HIV) Associated Dementia and Neuromuscular Diseases". The purpose of this pilot study is to evaluate the efficacy of Retrovir (AZT) in the treatment of AIDS-related dementia and various neuromuscular complications. HIV is both a lymphotropic and neurotropic virus which can affect both the central and peripheral nervous systems (CNS, PNS). There is evid...
What is the current status of trial NCT00002044?
This trial is currently completed. It is a NA study.
What interventions are being tested in trial NCT00002044?
The interventions under investigation include: Zidovudine (DRUG).
Who is sponsoring clinical trial NCT00002044?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.